196 related articles for article (PubMed ID: 31012504)
21. Targeted Covalent Inhibition of Telomerase.
Betori RC; Liu Y; Mishra RK; Cohen SB; Kron SJ; Scheidt KA
ACS Chem Biol; 2020 Mar; 15(3):706-717. PubMed ID: 32017522
[TBL] [Abstract][Full Text] [Related]
22. Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.
Chen CL; Chang DM; Chen TC; Lee CC; Hsieh HH; Huang FC; Huang KF; Guh JH; Lin JJ; Huang HS
Eur J Med Chem; 2013 Feb; 60():29-41. PubMed ID: 23279865
[TBL] [Abstract][Full Text] [Related]
23. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
24. Telomerase Inhibitor TMPyP4 Alters Adhesion and Migration of Breast-Cancer Cells MCF7 and MDA-MB-231.
Konieczna N; Romaniuk-Drapała A; Lisiak N; Totoń E; Paszel-Jaworska A; Kaczmarek M; Rubiś B
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151281
[TBL] [Abstract][Full Text] [Related]
25. Role of p53 transcription factor in determining the efficacy of telomerase inhibitors in cancer treatment.
Gala K; Jain M; Shah P; Pandey A; Garg M; Khattar E
Life Sci; 2024 Feb; 339():122416. PubMed ID: 38216120
[TBL] [Abstract][Full Text] [Related]
26. Selected ellipticine derivatives, known to target topoisomerase II, suppress the alternative lengthening of telomere (ALT) pathway in telomerase-negative cells.
Zencir S; Hsieh MH; Hsu JS; Ergun Y; Chou GL; Li TK; Teng SC; Topcu Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1671-1676. PubMed ID: 32333143
[TBL] [Abstract][Full Text] [Related]
27. Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes.
Gowan SM; Heald R; Stevens MF; Kelland LR
Mol Pharmacol; 2001 Nov; 60(5):981-8. PubMed ID: 11641426
[TBL] [Abstract][Full Text] [Related]
28. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment.
Ward RJ; Autexier C
Mol Pharmacol; 2005 Sep; 68(3):779-86. PubMed ID: 15939802
[TBL] [Abstract][Full Text] [Related]
29. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
Kelland LR
Eur J Cancer; 2005 May; 41(7):971-9. PubMed ID: 15862745
[TBL] [Abstract][Full Text] [Related]
30. Telomere length mediates the effects of telomerase on the cellular response to genotoxic stress.
Rubio MA; Davalos AR; Campisi J
Exp Cell Res; 2004 Aug; 298(1):17-27. PubMed ID: 15242758
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib-mediated down-regulation of telomerase and disruption of telomere homeostasis contributes to apoptosis of malignant cells.
Ci X; Li B; Ma X; Kong F; Zheng C; Björkholm M; Jia J; Xu D
Oncotarget; 2015 Nov; 6(35):38079-92. PubMed ID: 26472030
[TBL] [Abstract][Full Text] [Related]
32. Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies.
Jafri MA; Ansari SA; Alqahtani MH; Shay JW
Genome Med; 2016 Jun; 8(1):69. PubMed ID: 27323951
[TBL] [Abstract][Full Text] [Related]
33. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics.
Seimiya H; Muramatsu Y; Ohishi T; Tsuruo T
Cancer Cell; 2005 Jan; 7(1):25-37. PubMed ID: 15652747
[TBL] [Abstract][Full Text] [Related]
34. Telomerase inhibitors as anticancer therapy.
Akiyama M; Hideshima T; Munshi NC; Anderson KC
Curr Med Chem Anticancer Agents; 2002 Sep; 2(5):567-75. PubMed ID: 12678724
[TBL] [Abstract][Full Text] [Related]
35. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway.
Grobelny JV; Kulp-McEliece M; Broccoli D
Hum Mol Genet; 2001 Sep; 10(18):1953-61. PubMed ID: 11555632
[TBL] [Abstract][Full Text] [Related]
36. Telomerase inhibitor MST-312 induces apoptosis of multiple myeloma cells and down-regulation of anti-apoptotic, proliferative and inflammatory genes.
Ameri Z; Ghiasi S; Farsinejad A; Hassanshahi G; Ehsan M; Fatemi A
Life Sci; 2019 Jul; 228():66-71. PubMed ID: 31029779
[TBL] [Abstract][Full Text] [Related]
37. Telomere biology of pediatric cancer.
Tabori U; Dome JS
Cancer Invest; 2007; 25(3):197-208. PubMed ID: 17530490
[TBL] [Abstract][Full Text] [Related]
38. Effect of silencing key proteins in telomerase mechanism and alternative lengthening of telomeres mechanism in laryngeal cancer cells.
Xu Y; Wang X; Chen SM; Chen C; Wang Y; Xiao BK; Tao ZZ
Am J Otolaryngol; 2016; 37(6):552-558. PubMed ID: 27726944
[TBL] [Abstract][Full Text] [Related]
39. Telomeres and telomerase as targets for anticancer drug development.
Olaussen KA; Dubrana K; Domont J; Spano JP; Sabatier L; Soria JC
Crit Rev Oncol Hematol; 2006 Mar; 57(3):191-214. PubMed ID: 16469501
[TBL] [Abstract][Full Text] [Related]
40. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991.
Seimiya H; Oh-hara T; Suzuki T; Naasani I; Shimazaki T; Tsuchiya K; Tsuruo T
Mol Cancer Ther; 2002 Jul; 1(9):657-65. PubMed ID: 12479362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
